Spyre Therapeutics (NASDAQ:SYRE) Sets New 1-Year High – Here’s What Happened

Spyre Therapeutics, Inc. (NASDAQ:SYRE)’s share price reached a new 52-week high on Thursday . The company traded as high as $38.16 and last traded at $37.98, with a volume of 564792 shares traded. The stock had previously closed at $36.60.

Key Spyre Therapeutics News

Here are the key news stories impacting Spyre Therapeutics this week:

• Positive Sentiment: BTIG Research reaffirmed its “buy” rating and kept a $70 price target (roughly +62% upside vs. current levels), signaling strong buy-side conviction from a sell-side firm. BTIG Reaffirms Buy, $70 PT
• Positive Sentiment: Wells Fargo raised its price target to $50 and assigned an “overweight” rating, providing additional analyst support that likely helped lift the stock. Wells Fargo Raises PT to $50
• Positive Sentiment: Spyre reported a strong cash position — $757M in cash, equivalents and marketable securities as of 12/31/25 — and said that runway is expected into H2 2028, reducing near-term financing risk. The company also completed an offering in Oct 2025 and added a Chief Commercial Officer. Q4 & Corporate Update
• Positive Sentiment: Management reiterated an aggressive 2026 clinical cadence: up to six proof-of-concept readouts across the SKYLINE and SKYWAY Phase 2 programs (including Part A readouts starting in Q2 and multiple basket-study sub-readouts later in the year), which creates several near-term clinical catalysts. Clinical Readouts and Timeline
• Neutral Sentiment: Spyre announced presentations at the 21st ECCO Congress showcasing SPY003’s differentiated profile and preclinical combo data — supportive from a scientific/visibility standpoint but not an immediate financial catalyst. ECCO Presentations
• Negative Sentiment: Spyre missed the quarterly EPS consensus (reported -$0.70 vs. est. -$0.66), a modest miss that may temper sentiment for investors focused on near-term financials. Earnings Release

Wall Street Analysts Forecast Growth

Several equities research analysts have weighed in on SYRE shares. BTIG Research reissued a “buy” rating and issued a $70.00 price target on shares of Spyre Therapeutics in a report on Friday. Wall Street Zen cut shares of Spyre Therapeutics from a “hold” rating to a “sell” rating in a research note on Saturday. Weiss Ratings reissued a “sell (e+)” rating on shares of Spyre Therapeutics in a research report on Monday, December 29th. Citigroup started coverage on shares of Spyre Therapeutics in a research note on Wednesday, December 17th. They set a “buy” rating and a $64.00 price target on the stock. Finally, Mizuho upgraded shares of Spyre Therapeutics to a “strong-buy” rating in a research note on Thursday, December 18th. Two analysts have rated the stock with a Strong Buy rating, seven have assigned a Buy rating and one has assigned a Sell rating to the stock. According to data from MarketBeat, Spyre Therapeutics presently has a consensus rating of “Buy” and an average target price of $53.44.

Spyre Therapeutics Trading Up 14.3%

The company has a market capitalization of $3.35 billion, a PE ratio of -20.77 and a beta of 3.15. The business’s 50-day simple moving average is $33.40 and its 200-day simple moving average is $25.29.

Spyre Therapeutics (NASDAQ:SYRE) last released its quarterly earnings data on Thursday, February 26th. The company reported ($0.70) EPS for the quarter, missing the consensus estimate of ($0.66) by ($0.04). Sell-side analysts forecast that Spyre Therapeutics, Inc. will post -4.46 EPS for the current fiscal year.

Insiders Place Their Bets

In other Spyre Therapeutics news, CEO Cameron Turtle sold 15,000 shares of Spyre Therapeutics stock in a transaction dated Monday, February 2nd. The stock was sold at an average price of $32.80, for a total transaction of $492,000.00. Following the completion of the transaction, the chief executive officer owned 657,540 shares in the company, valued at approximately $21,567,312. This trade represents a 2.23% decrease in their position. The transaction was disclosed in a filing with the SEC, which is accessible through this link. Over the last 90 days, insiders sold 45,000 shares of company stock worth $1,387,500. 15.43% of the stock is currently owned by company insiders.

Institutional Trading of Spyre Therapeutics

Hedge funds have recently modified their holdings of the stock. Invesco Ltd. raised its position in Spyre Therapeutics by 197.7% during the fourth quarter. Invesco Ltd. now owns 150,934 shares of the company’s stock valued at $4,945,000 after acquiring an additional 100,232 shares in the last quarter. VARCOV Co. purchased a new stake in Spyre Therapeutics in the 4th quarter worth approximately $262,000. Virtus Investment Advisers LLC grew its stake in shares of Spyre Therapeutics by 23.2% during the 4th quarter. Virtus Investment Advisers LLC now owns 7,913 shares of the company’s stock worth $259,000 after purchasing an additional 1,488 shares during the period. Susquehanna Portfolio Strategies LLC increased its holdings in shares of Spyre Therapeutics by 144.3% during the 4th quarter. Susquehanna Portfolio Strategies LLC now owns 53,101 shares of the company’s stock valued at $1,740,000 after purchasing an additional 31,362 shares in the last quarter. Finally, Tudor Investment Corp ET AL purchased a new position in shares of Spyre Therapeutics during the 4th quarter valued at approximately $332,000. Hedge funds and other institutional investors own 80.39% of the company’s stock.

About Spyre Therapeutics

Spyre Therapeutics, Inc is a clinical-stage biotechnology company focused on the discovery and development of novel immunotherapies for cancer. The company leverages proprietary protein engineering and biologics design platforms to create targeted molecules intended to enhance anti-tumor immune responses and inhibit tumor growth. Its preclinical pipeline comprises multiple candidate therapies for solid tumor and hematologic oncology indications.

Established by a team with deep expertise in protein design, immunology and translational research, Spyre Therapeutics collaborates with leading academic institutions and research organizations to accelerate its discovery efforts.